Blog

The five drug development questions that bring sponsors to pharmacometrics

Sponsors rarely come to pharmacometrics because they need a model. They come with a development…

Rik de GreefAugust 24, 2026

On-Demand Webinar

Beyond Trial and Error: Model-Informed Formulation Development in Practice

Learn how model-informed formulation development and PBPK modeling can guide formulation strategy, bioequivalence, and biowaiver…

Siri Kalyan ChirumamillaAugust 24, 2026

Fact Sheet

Model-Based Meta-Analysis (MBMA): Real-World Examples

See real-world examples of how model-based meta-analysis (MBMA) uses existing clinical evidence to predict trial…

CertaraAugust 24, 2026

On-Demand Webinar

How to Choose Your First-in-Human Dose Approach

MABEL, PK/PD, mPAD, PBPK, or QSP? Certara scientists on matching your first-in-human dose prediction approach…

CertaraAugust 17, 2026

Blog

MBMA data curation: How AI and expert meta-analysts get it right, fast

In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…

Matt Zierhut, PhD MBAAugust 14, 2026

Blog

A model-informed approach to radioligand therapy dosing under Project Optimus

Explore how targeted radionuclide therapy dosing uses QSP, biologically effective dose (BED), and exposure-response modeling…

Hunter Stephens, PhDAugust 13, 2026

White Paper

Managing drug-drug interaction (DDI) risk for patients in clinical trials

Discover how DIDB® helps clinical teams assess drug-drug interaction risk, develop prohibited medication lists, &…

Katie Owens, PhDAugust 12, 2026

On-Demand Webinar

Investor panel: What it takes to build a fundable biotech – with Life Science Nation

Investors, founders, and drug development strategists on what makes an early-stage biotech investable beyond the…

CertaraAugust 6, 2026

Publication

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

Explore advances in model-informed precision dosing (MIPD) for pediatric antimicrobial therapy, including population PK modeling,…

CertaraJuly 29, 2026

Poster

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

See how quantitative pharmacology and PBPK modeling supported first in human dose selection for a…

CertaraJuly 20, 2026

Drug Development

The five drug development questions that bring sponsors to pharmacometrics

Beyond Trial and Error: Model-Informed Formulation Development in Practice

Model-Based Meta-Analysis (MBMA): Real-World Examples

How to Choose Your First-in-Human Dose Approach

MBMA data curation: How AI and expert meta-analysts get it right, fast

A model-informed approach to radioligand therapy dosing under Project Optimus

Managing drug-drug interaction (DDI) risk for patients in clinical trials

Investor panel: What it takes to build a fundable biotech – with Life Science Nation

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

Newsletter sign up

Quick links

Solutions

Contact